Andre; Pascale
Patent Applications and Registrations
Patent applications and USPTO patent grants for Andre; Pascale.The latest application filed is for "treatment regimens using anti-nkg2a antibodies".
Company Profile
11.21.30
- Andre; Pascale - Marseilles FR
- ANDRE; PASCALE - MARSEILLE FR
Patent Activity
| Patent | Date |
|---|---|
| Treatment of cancers using anti-NKG2A agents Grant 11,225,519 - Andre , et al. January 18, 2 | 2022-01-18 |
| Treatment Regimens Using Anti-nkg2a Antibodies App 20210238285 - ANDRE; PASCALE ; et al. | 2021-08-05 |
| Neutralization Of Inhibitory Pathways In Lymphocytes App 20210122821 - ANDRE; PASCALE ; et al. | 2021-04-29 |
| Neutralization of inhibitory pathways in lymphocytes Grant 10,870,700 - Andre , et al. December 22, 2 | 2020-12-22 |
| Neutralization Of Inhibitory Pathways In Lymphocytes App 20200332008 - ANDRE; PASCALE ; et al. | 2020-10-22 |
| Treatment Regimens Using Anti-nkg2a Antibodies App 20200299383 - ANDRE; PASCALE ; et al. | 2020-09-24 |
| Neutralization of inhibitory pathways in lymphocytes Grant 10,711,063 - Andre , et al. | 2020-07-14 |
| Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer Grant 10,688,180 - Graziano , et al. | 2020-06-23 |
| Treatment regimens using anti-NKG2A antibodies Grant 10,676,523 - Andre , et al. | 2020-06-09 |
| Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma Grant 10,494,433 - Andre , et al. De | 2019-12-03 |
| Treatment Of Cancers Using Anti-nkg2a Agents App 20190322744 - ANDRE; PASCALE ; et al. | 2019-10-24 |
| Treatment of cancers using anti-NKG2A agents Grant 10,329,348 - Andre , et al. | 2019-06-25 |
| Monoclonal Antibodies Against Nkg2a App 20190135938 - Moretta; Alessandro ; et al. | 2019-05-09 |
| Neutralization Of Inhibitory Pathways In Lymphocytes App 20190031755 - ANDRE; PASCALE ; et al. | 2019-01-31 |
| Monoclonal antibodies against NKG2A Grant 10,160,810 - Moretta , et al. Dec | 2018-12-25 |
| Combination Of Anti-kir And Anti-ctla-4 Antibodies To Treat Cancer App 20180117147 - GRAZIANO; Robert F. ; et al. | 2018-05-03 |
| Methods for treatment of recurrent hematological malignancies Grant 9,844,593 - Andre , et al. December 19, 2 | 2017-12-19 |
| Treatment Of Cancers Using Anti-nkg2a Agents App 20170313773 - ANDRE; PASCALE ; et al. | 2017-11-02 |
| Treatment Regimens Using Anti-nkg2a Antibodies App 20170298131 - ANDRE; PASCALE ; et al. | 2017-10-19 |
| Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer Grant 9,789,182 - Graziano , et al. October 17, 2 | 2017-10-17 |
| Neutralization Of Inhibitory Pathways In Lymphocytes App 20170291947 - ANDRE; PASCALE ; et al. | 2017-10-12 |
| Combination Of Anti-kir And Anti-cs1 Antibodies To Treat Multiple Myeloma App 20160257750 - ANDRE; Pascale ; et al. | 2016-09-08 |
| Anti-kir Antibodies For The Treatment Of Inflammatory And Autoimmune Disorders App 20150376275 - Romagne; Francois ; et al. | 2015-12-31 |
| Human Anti-kir Antibodies App 20150344576 - Moretta; Alessandro ; et al. | 2015-12-03 |
| Combination Of Anti-kir And Anti-ctla-4 Antibodies To Treat Cancer App 20150283234 - Graziano; Robert F. ; et al. | 2015-10-08 |
| Human Anti-kir Antibodies App 20150191547 - Moretta; Alessandro ; et al. | 2015-07-09 |
| Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders Grant 9,067,997 - Romagne , et al. June 30, 2 | 2015-06-30 |
| Monoclonal Antibodies Against Nkg2a App 20150132316 - MORETTA; ALESSANDRO ; et al. | 2015-05-14 |
| Monoclonal Antibodies Against Nkg2a App 20150125464 - MORETTA; ALESSANDRO ; et al. | 2015-05-07 |
| Monoclonal antibodies against NKG2A Grant 8,993,319 - Moretta , et al. March 31, 2 | 2015-03-31 |
| Human anti-KIR antibodies Grant 8,981,065 - Moretta , et al. March 17, 2 | 2015-03-17 |
| Compositions And Methods For Regulating Nk Cell Activity App 20140193430 - PADKJAER; SOREN BERG ; et al. | 2014-07-10 |
| Compositions and methods for regulating NK cell activity Grant 8,637,258 - Padkjaer , et al. January 28, 2 | 2014-01-28 |
| Nucleic acids encoding human anti-kir antibodies Grant 8,614,307 - Moretta , et al. December 24, 2 | 2013-12-24 |
| Human Anti-kir Anitbodies App 20130287770 - Moretta; Alessandro ; et al. | 2013-10-31 |
| Nk Cell Modulating Treatments And Methods For Treatment Of Hematological Malignancies App 20130251711 - Andre; Pascale ; et al. | 2013-09-26 |
| Anti-kir Antibodies For The Treatment Of Inflammatory And Autoimmune Disorders App 20120328615 - Romagne; Francois ; et al. | 2012-12-27 |
| Human Anti-kir Antibodies App 20120208237 - Moretta; Alessandro ; et al. | 2012-08-16 |
| Human anti-KIR antibodies Grant 8,119,775 - Moretta , et al. February 21, 2 | 2012-02-21 |
| Monoclonal Antibodies Against NKG2A App 20110229486 - Moretta; Allessandro ; et al. | 2011-09-22 |
| Compositions and Methods for Regulating NK Cell Activity App 20100291110 - Padkjaer; Soren Berg ; et al. | 2010-11-18 |
| Monoclonal Antibodies Against Nkg2a App 20090208416 - Moretta; Alessandro ; et al. | 2009-08-20 |
| Compositions and methods for regulating NK cell activity App 20090191213 - Padkjaer; Soren Berg ; et al. | 2009-07-30 |
| Human Anti-Kir Antibodies App 20090081240 - Moretta; Alessandro ; et al. | 2009-03-26 |
| Compositions and methods for regulating NK cell activity App 20060280740 - Padkjaer; Soren Berg ; et al. | 2006-12-14 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 